Related Experiment Video
Updated: Nov 6, 2025

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
Death rates in the U.S. due to Leukodystrophies with pediatric forms
Amy L Barczykowski1,2, Thomas J Langan3,4, Adeline Vanderver5,6
1Population Health Observatory, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA.
Insights
Leukodystrophies (LDs) impact children and adults, with pediatric fatality cases declining then stabilizing. This study provides crucial epidemiological data for rare disease research and newborn screening programs.
Area of Science:
- Neurology
- Epidemiology
- Genetics
Background:
- Leukodystrophies (LDs) are a group of rare genetic disorders affecting the brain's white matter.
- Accurate epidemiological data for LDs, particularly those with pediatric forms, are often lacking.
- Understanding mortality rates and prevalence is essential for resource allocation and patient care.
Observation:
- National mortality and state death certificate records were analyzed for 23 LDs with pediatric forms.
- ICD-10 codes identified deaths related to LDs, with data categorized using state-specific proportions.
- Calculations incorporated population sizes and average lifespans to estimate disease-specific rates.
Findings:
- An estimated 1.513 per million children (0-17 years) and 0.194 per million adults (≥18 years) died from these LDs.
- The average age of death for pediatric LD cases was 5.2 years, and 42.3 years for adults.
- Prevalence of pediatric fatality cases decreased from 1999-2007, then remained constant at 6.2 per million children annually through 2012.
Implications:
- The findings provide vital epidemiological information for rare diseases like LDs.
- This data supports newborn screening programs, research funding, and specialized care centers.
- The methodology is adaptable for studying other rare diseases, enhancing public health surveillance.
Abstract:
To use national mortality and state death certificate records to estimate disease specific mortality rates among pediatric and adult populations for 23 leukodystrophies (LDs) with pediatric forms. Additionally, to calculate yearly prevalence and caseload of the most severe LD cases that will eventually result in pediatric death (i.e., pediatric fatality cases). Death certificate records describing cause of death were collected from states based on 10 ICD-10 codes associated with the 23 LDs. Deaths in the U.S. with these codes were distributed into categories based on proportions identified in state death certificate data. Mortality rates, prevalence, and caseload were calculated from resulting expected numbers, population sizes, and average lifetimes. An estimated 1.513 per 1,000,000 0-17 year old's died of these LDs at average age 5.2 years and 0.194 for those ≥18 at an average age of 42.3 years. Prevalence of pediatric fatality cases of these LDs declined from 1999 through 2007 and then remained constant at 6.2 per million children per year through 2012. Epidemiological information, currently lacking for rare diseases, is useful to newborn screening programs, research funding agencies, and care centers for LD patients. Methods used here are generally useful for studying rare diseases.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Lysosomal Hydrolases
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Drug Dosing: Infants and Children

